199 related articles for article (PubMed ID: 36534647)
1. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.
González NL; Moscatelli G; Moroni S; Ballering G; Jurado L; Falk N; Bochoeyer A; Goldsman A; Grippo M; Freilij H; Garcia Bournissen F; Chatelain E; Altcheh J
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010968. PubMed ID: 36534647
[TBL] [Abstract][Full Text] [Related]
2. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
3. Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period.
Suasnábar S; Olivera LV; Arias E; Bizai ML; Bottasso O; Arias E; Fabbro D
Acta Trop; 2021 Oct; 222():106050. PubMed ID: 34302770
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
[TBL] [Abstract][Full Text] [Related]
5. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of combined therapy with amiodarone and low-dose benznidazole in a mouse model of chronic Trypanosoma cruzi infection.
Barbosa JMC; Pedra-Rezende Y; Mata-Santos HA; Vilar-Pereira G; Melo TG; Ramos IP; Gibaldi D; Moreira OC; Nunes DF; Batista MM; Lannes-Vieira J; Daliry A; Salomão K
Biomed Pharmacother; 2024 Jun; 175():116742. PubMed ID: 38754265
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Evaluation in the Acute Phase of Chagas' Disease with Post-Treatment Evolution in Patients Attended in the State of Amazonas, Brazil.
Ortiz JV; Pereira BVM; Couceiro KDN; Silva MRHDSE; Doria SS; Silva PRLD; Lira EDF; Guerra MDGVB; Guerra JAO; Ferreira JMBB
Arq Bras Cardiol; 2019 Mar; 112(3):240-246. PubMed ID: 30916205
[TBL] [Abstract][Full Text] [Related]
8. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial.
Moreira OC; Ramírez JD; Velázquez E; Melo MF; Lima-Ferreira C; Guhl F; Sosa-Estani S; Marin-Neto JA; Morillo CA; Britto C
Acta Trop; 2013 Jan; 125(1):23-31. PubMed ID: 22982466
[TBL] [Abstract][Full Text] [Related]
9. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G
Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study.
Colantonio LD; Prado N; Segura EL; Sosa-Estani S
PLoS Negl Trop Dis; 2016 May; 10(5):e0004651. PubMed ID: 27158908
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal follow up of serological response in children treated for Chagas disease.
Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
[TBL] [Abstract][Full Text] [Related]
12. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
[TBL] [Abstract][Full Text] [Related]
13. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
Gallerano RR; Sosa RR
Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
[TBL] [Abstract][Full Text] [Related]
15. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
16. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
17. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A
Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588
[TBL] [Abstract][Full Text] [Related]
18. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
19. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE;
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557
[TBL] [Abstract][Full Text] [Related]
20. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
